Gland Pharma · NSE: GLAND · BSE: 543245
Q3 FY22 results · Oct–Dec 2021
Gland Pharma reported revenue from operations of ₹1,063.33 crore and net profit of ₹273.03 crore for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,063.33 | — | — | 1,080.47 | −1.6% |
| Other income | 45.67 | — | — | 51.20 | −10.8% |
| Total income | 1,108.99 | — | — | 1,131.67 | −2.0% |
| Profit before tax | 365.56 | — | — | 400.67 | −8.8% |
| Net profit for the period | 273.03 | — | — | 302.08 | −9.6% |
| EPS, basic (₹) | 16.62 | — | — | 18.37 | −9.5% |
| Net margin (%) | 25.7 | — | 28.0 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,063.33 | 859.42 | +23.7% | 1,080.47 | −1.6% |
| Other income | 45.67 | 35.13 | +30.0% | 51.20 | −10.8% |
| Total income | 1,108.99 | 894.55 | +24.0% | 1,131.67 | −2.0% |
| Profit before tax | 365.92 | 273.24 | +33.9% | 400.70 | −8.7% |
| Net profit for the period | 273.38 | 204.11 | +33.9% | 302.12 | −9.5% |
| EPS, basic (₹) | 16.64 | 12.83 | +29.7% | 18.37 | −9.4% |
| Net margin (%) | 25.7 | 23.7 | 28.0 |
Consolidated
- Filed with BSE
- 21 Jan 2022, 17:17 IST
- Board meeting
- 21 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 21 Jan 2022, 17:17 IST
- Board meeting
- 21 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE